Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations
Payam Tabarsi, Nassim Anjidani, Ramin Shahpari, Masoud Mardani, Araz Sabzvari, Babak Yazdani, Khashayar Roshanzamir, Behnam Bayatani, Ali Taheri, Nikolai Petrovsky, Lei Li, Saghar Barati
Topics & Concepts
ImmunogenicityVirologyAdjuvantSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationRecombinant DNAMedicineSpike Protein2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)BiologyImmunologyAntibodyGeneticsDiseaseOutbreakInternal medicineGeneInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchBacterial Infections and VaccinesViral gastroenteritis research and epidemiology